AZD0022, AZD0022, Erbitux 5 mg/mL solution for infusion
D7080C00001
Phase 2 small_molecule active
Quick answer
AZD0022, AZD0022, Erbitux 5 mg/mL solution for infusion for Non Small Cell Lung Cancer Colorectal Cancer Pancreatic Ductal Adenocarcinoma is a Phase 2 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Non Small Cell Lung Cancer Colorectal Cancer Pancreatic Ductal Adenocarcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active